Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Opening Session Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Apr

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Opening Session Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds

American Cancer Society Announces New Pediatric Adolescent and Young Adult Cancer Journal

Colorectal Cancer Duloxetine Not Effective in Preventing Oxaliplatin-Induced Peripheral Neuropathy

Advanced Prostate Cancer Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide

CLL Linked to Increased Skin Cancer Risk and Mortality